ADME/PK as part of a rational approach to drug discovery.

Rational drug discovery requires an early appraisal of all factors impacting on the likely success of a drug candidate in the subsequent preclinical, clinical and commercial phases of drug development. The study of absorption, distribution, metabolism, excretion and pharmacokinetics (ADME/PK) has developed into a relatively mature discipline in drug discovery through the application of well-established in vitro and in vivo methodologies. The availability of improved analytical and automation technologies has dramatically increased our ability to dissect out the fundamentals of ADME/PK through the development of increasingly powerful in silico methods. This is fuelling a shift away from the traditional, empirical nature of ADME/PK towards a more rational, in cerebro approach to drug design.

[1]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[2]  R. Hurst,et al.  Properties of an immortalised vascular endothelial/glioma cell co‐culture model of the blood‐brain barrier , 1996, Journal of Cellular Physiology.

[3]  Peter J. Eddershaw,et al.  Advances in in vitro drug metabolism screening , 1999 .

[4]  Pickett,et al.  Computational methods for the prediction of 'drug-likeness' , 2000, Drug discovery today.

[5]  D A Smith,et al.  Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics , 1996, Medicinal research reviews.

[6]  Mark A. Murcko,et al.  Virtual screening : an overview , 1998 .

[7]  T. Kennedy.  Managing the drug discovery/development interface , 1997 .

[8]  P. Woollard,et al.  Cassette dosing: rapid in vivo assessment of pharmacokinetics , 1998 .

[9]  B. W. Penman,et al.  Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. , 1997, Analytical biochemistry.

[10]  W. Jusko,et al.  Characterization of Pharmacodynamic Recession Slopes for Direct and Indirect Response Models , 1998, Journal of Pharmacokinetics and Biopharmaceutics.

[11]  G. Caldwell.  Compound optimization in early- and late-phase drug discovery: acceptable pharmacokinetic properties utilizing combined physicochemical, in vitro and in vivo screens. , 2000, Current opinion in drug discovery & development.

[12]  Rodrigues Ad,et al.  Preclinical drug metabolism in the age of high-throughput screening: an industrial perspective. , 1997 .

[13]  J. Tolan,et al.  MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. , 1999, Journal of pharmaceutical sciences.

[14]  S. Chong,et al.  In Vitro Permeability Through Caco-2 Cells is not Quantitatively Predictive of in Vivo Absorption for Peptide-Like Drugs Absorbed via the Dipeptide Transporter System , 2004, Pharmaceutical Research.

[15]  R. Obach,et al.  Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[16]  S. Walker,et al.  Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). , 1988, British journal of clinical pharmacology.

[17]  G. Granneman,et al.  Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions , 1997, Clinical pharmacokinetics.

[18]  Evans,et al.  Approaches to higher-throughput pharmacokinetics (HTPK) in drug discovery. , 2000, Drug discovery today.

[19]  P J Sinko.  Drug selection in early drug development: screening for acceptable pharmacokinetic properties using combined in vitro and computational approaches. , 1999, Current opinion in drug discovery & development.

[20]  R J Riley,et al.  Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.

[21]  B. Ring,et al.  In vitro methods for assessing human hepatic drug metabolism: their use in drug development. , 1993, Drug metabolism reviews.

[22]  J H Lin,et al.  Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[23]  F. Roux,et al.  Synergistic stimulation of gamma‐glutamyl transpeptidase and alkaline phosphatase activities by retinoic acid and astroglial factors in immortalized rat brain microvessel endothelial cells , 1996, Journal of cellular physiology.

[24]  C. Hansch,et al.  Quantitative structure-activity relationships of cytochrome P-450. , 1993, Drug metabolism reviews.

[25]  W J Jusko,et al.  Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. , 1998, British journal of clinical pharmacology.